A crossover comparison of intermittent oral and intrvenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients

Mineral and Electrolyte Metabolism

Volumn 23, Issue 1, 1997, Pages 13-18

  Peng, Sheng Jeng ^a   Yang, Chwei Shiun ^a   Ferng, Shyang Hwa ^a   Chen, Lung Yu ^a  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Calcitriol; Intermittent pulse therapy; Parathyroid hormone; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

CALCITRIOL; CALCIUM CARBONATE; PARATHYROID HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

ADMINISTRATION, ORAL; ADULT; ALKALINE PHOSPHATASE; CALCITRIOL; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 0031049857     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Coburn JW, Slatopolsky E: Vitamin D, parathyroid hormone, and the renal osteodystrophies; in Brenner B, Rector F (eds): The Kidney. Philadelphia, Saunders, 1991, pp 2036-2120.
2. Delmez JA: Long-term complications of dialysis: Pathogenetic factors with special reference to bone. Kidney Int 1993;43(suppl 41):S116- S120.
3. Johnson WJ: Optimum dialysate calcium concentration during maintenance hemodialysis. Nephron 1976;17:241-258.
4. Raman A, Chong YK, Sreenevasan GA: Effects of varying dialysate calcium concentrations on the plasma calcium fractions in patients on dialysis. Nephron 1976;16:181- 187.
5. Asad SN, Ellis KJ, Conn SH, lotted JM: Changes in total body calcium on prolonged maintenance hemodialysis with high and low dialysate calcium. Nephron 1979;23:223-227.
6. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis, N Engl J Med 1986;315:157-161.
7. Anelli A, Brancaccio D, Damasso R, Padovese P, Gallieni M, Garella S: Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Nephron 1989;52: 125-132.
8. Fournier A, Moriniere P, Sebert JL, Dkhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M: Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int 1986;29 (suppl 18):S114-S119.
9. Hercz G, Kraut JA, Andress DA, Howard N, Roberts C, Shinaberger JH, Sherrard DJ, Coburn JW: Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab 1986;12:314-319.
10. Williams B, Vennegoor M, O'Nunan T, Walls J: The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure. Nephrol Dial Transplant 1989;4:725-729.
11. Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN: Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 1986;108:767-770.
12. Oettinger CW, Oliver JC, Macon EJ: The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients. J Am Soc Nephrol 1992;3:995-1001.
13. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martili KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-2143.
14. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321: 274-279.
15. Salusky IB, Goodman WG, Noms KC, Horst R, Fine RN, Cobum JW: Bioavailability of calcitriol after oral, intravenous, and intraperitoneal doses in dialysis patients, in Norman AW, Schaefer K, Grigoleit HG, Herrath DV (eds): Vitamin D, Molecular, Cellular and Clinical Endocrinology. Berlin, de Gruyter, 1988, pp 783-784.
16. Cobum JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney hit 1990;38:(suppl 29):S54-S61.
17. Schaefer K, Umlauf E, Herrath DV: Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis 1992; 19:460-464.
18. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G, on behalf of the Italian Group for the Study of Intravenous Calcitriol: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 1992;42:1191-1198.
19. Sprague SM, Moe SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 1992;19:532-539.
20. Ljunghall S, Althoff P, Fellström B, Marjanovic B, Nisell J, Weiss L, Side L: Effects on serum parathyroid hormone of intravenous treatment with alpha-calcidol on chronic hemodialysis. Nephron 1990;55:380-385.
21. 3 in patients on chronic hemodialysis. Am J Nephrol 1992;12:311-318.
22. 2 as sole phosphate binder. Nephron 1992;60:154-163.
23. 3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991;57:23-28.
24. Martin KJ, Ballal HS, Domoto DT, Blalock S, Weindel M: Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: Preliminary observations. Am J Kidney Dis 1992;19:540-545.
25. Kwan JTC, Almond MK, Beer JC, Noonan K, Evans SJW, Cunningham J: 'Pulse' oral calcitriol in uraemic patients: Rapid modification of parathyroid response to calcium. Nephrol Dial Transplant 1992;7:829-834.
26. Fischer ER, Harris DCH: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993;40:216- 220.
27. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B: Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. Kidney Int 1988;34:840-844.
28. Mactier RA, Van Stone J, Cox A, Van Stone M, Twardowski Z: Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 1987;28:222-226.
29. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J: Long- term effects of calcium carbonate and 2.5 mEq/ liter calcium dialysate on mineral metabolism. Kidney Int 1985;36:897-903.
30. Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J: High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: Effective phosphate control and aluminum avoidance in haemodialysis patients. Nephrol Dial Transplant 1989;4:105- 109.
31. 3 and low dialysate calcium. Kidney Int 1993;43 (suppl 41):S121-S124.
32. Cobum JW: Mineral metabolism and renal bone disease: Effects of CAPD versus hemodialysis. Kidney Int 1993;43(suppl 40):S92- S100.
33. Malberti F, Montoli A, Surian M: Long-term effect of low calcium dialysate on parathyroid activity in dialysis patients treated with calcium carbonate as a phosphate binder (letter). Nephrol Dial Transplant 1989;4:758-759.
34. Argiles À, Kerr PG, Canaud B, Flavier JL, Mion C: Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 1993;43:630-640.
35. Zehnder C, Kränzlin M, Kizhakekkara R: Effects of calcium salts and different calcium dialysate concentrations on the mineral metabolism of hemodialysis patients (abstract). Kidney Int 1993 ;44:265-266.
36. 3 on the secretion of parathyroid hormone in hemodialysis patients. Clin Nephrol 1992;38:145- 148.
37. Andress DL, Endres DB, Maloney NA, Kopp JB, Coburn JW, Sherrard DJ: Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab 1986;63:1163-1169.
38. Solal MEC, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A: Comparison of intact, midregion, and carboxyl terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991;73: 516-524.
39. Morita A, Tabata T, Koyama H, Emoto M, Inoue T, Nishizawa Y, Morii H: A two-site immunochemiluminometric assay for intact parathyroid hormone and its clinical utility in hemodialysis patients. Clin Nephrol 1992;38: 154-157